Non-Melanoma Skin Cancers

Jerry Brewer, MD, MS, shared pearls on reasons to avoid or discontinue Mohs surgery and keeping calm with stressed, vulnerable patients.

Katie Schlenker, DO, emphasizes the importance of empathy during tough conversations with skin cancer patients with few to no treatment options left.

Golda explains why he prefers using tranexamic acid to control bleeding in granulated wounds.

An ACMS poster session indicates Mohs micrographic surgeons and histology technicians are at high risk of developing musculoskeletal injuries from their day-to-day tasks.

Laura Rezac, MD and her colleagues evaluated a teledermatology postoperative follow-up model after Mohs Micrographic surgery.

Caleb Kovell, MD and Junqian Zhang, MD demonstrated how teaming up increases the likelihood for positive patient outcomes in Mohs cases on the genitalia and perianal region.

The question was a conversation starter after an ACMS clinical abstract presentation.

An ACMS poster session delves into the role artificial intelligence can play in the treatment of basal cell carcinoma.

A poster session and ACMS keynote speaker Anant Madabhushi, MS, PhD, both delve into the use of AI in Mohs surgery.

Bar will share insight on foldover interpolated flaps for full thickness of nasal defects.

From explaining how medications work and should be taken to reviewing potential adverse effects and financial details, pharmacists are crucial resources for patients undergoing treatment for skin cancer.

The task force defined screening as a visual skin exam by a primary care clinician for this recommendation.

Verrica Pharmaceuticals is developing a potentially first-in-class oncolytic peptide.

Laura Ferris, MD, PhD and Andrew Weinstein, MD, FAAD discuss the importance of multidisciplinary care in their patients with locally advanced basal cell carcinoma, reinforcing the role of the dermatologist in the care plan.

With the advent of immunotherapy, the 1-year survival rate for patients with metastatic melanoma has increased from 25% to 50%.

An expert in the management of basal cell carcinoma stresses the importance of early identification and engaging a multidisciplinary team in the management of patients suffering from this condition.

John Strasswimmer MD, PhD provides a recap of a panel discussion from Winter Clinical in Miami, Florida highlighting the management challenges providers face in patients with locally advanced basal cell carcinoma.